BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37427847)

  • 1. The 2023 Bethesda System for Reporting Thyroid Cytopathology.
    Ali SZ; Baloch ZW; Cochand-Priollet B; Schmitt FC; Vielh P; VanderLaan PA
    Thyroid; 2023 Sep; 33(9):1039-1044. PubMed ID: 37427847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 2023 Bethesda System for reporting thyroid cytopathology.
    Ali SZ; Baloch ZW; Cochand-Priollet B; Schmitt FC; Vielh P; VanderLaan PA
    J Am Soc Cytopathol; 2023; 12(5):319-325. PubMed ID: 37438235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bethesda 2023: A new terminology for thyroid cytopathology].
    Cochand-Priollet B; Vielh P
    Ann Pathol; 2024 Feb; 44(1):30-35. PubMed ID: 38233236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comprehensive Approach to the Thyroid Bethesda Category III (AUS) in the Transition Zone Between 2nd Edition and 3rd Edition of The Bethesda System for Reporting Thyroid Cytopathology: Subcategorization, Nuclear Scoring, and More.
    Bagıs M; Can N; Sut N; Tastekin E; Erdogan EG; Bulbul BY; Sezer YA; Kula O; Demirtas EM; Usta I
    Endocr Pathol; 2024 Mar; 35(1):51-76. PubMed ID: 38280141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reproducibility of atypia of undetermined significance/follicular lesion of undetermined significance category using the bethesda system for reporting thyroid cytology when reviewing slides from different institutions: A study of interobserver variability among cytopathologists.
    Padmanabhan V; Marshall CB; Akdas Barkan G; Ghofrani M; Laser A; Tolgay Ocal I; David Sturgis C; Souers R; Kurtycz DF
    Diagn Cytopathol; 2017 May; 45(5):399-405. PubMed ID: 28217980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining molecular testing and the Bethesda category III:VI ratio for thyroid fine-needle aspirates: A quality-assurance metric for evaluating diagnostic performance in a cytopathology laboratory.
    Gokozan HN; Dilcher TL; Alperstein SA; Qiu Y; Mostyka M; Scognamiglio T; Solomon JP; Song W; Rennert H; Beg S; Stern E; Goyal A; Siddiqui MT; Heymann JJ
    Cancer Cytopathol; 2022 Apr; 130(4):259-274. PubMed ID: 34962713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in The Bethesda System for Reporting Thyroid Cytopathology.
    Faquin WC; Wong LQ; Afrogheh AH; Ali SZ; Bishop JA; Bongiovanni M; Pusztaszeri MP; VandenBussche CJ; Gourmaud J; Vaickus LJ; Baloch ZW
    Cancer Cytopathol; 2016 Mar; 124(3):181-7. PubMed ID: 26457584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the bethesda system for reporting thyroid cytopathology and similar precursor thyroid cytopathology reporting schemes.
    Wong LQ; Baloch ZW
    Adv Anat Pathol; 2012 Sep; 19(5):313-9. PubMed ID: 22885380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [On-site fine-needle aspiration cytology of thyroid nodules. Quality assurance of the Bethesda System for Reporting Thyroid Cytopathology (2008)].
    Bak M; Péter I; Nyári T; Simon P; Újlaky M; Boér A; Kásler M
    Orv Hetil; 2015 Oct; 156(41):1661-6. PubMed ID: 26551169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Presence of Hürthle Cells Does Not Increase the Risk of Malignancy in Most Bethesda Categories in Thyroid Fine-Needle Aspirates.
    Ren Y; Kyriazidis N; Faquin WC; Soylu S; Kamani D; Saade R; Torchia N; Lubitz C; Davies L; Stathatos N; Stephen AE; Randolph GW
    Thyroid; 2020 Mar; 30(3):425-431. PubMed ID: 32013786
    [No Abstract]   [Full Text] [Related]  

  • 11. A Large Thyroid Fine Needle Aspiration Biopsy Cohort with Long-Term Population-Based Follow-Up.
    Ng DL; van Zante A; Griffin A; Hills NK; Ljung BM
    Thyroid; 2021 Jul; 31(7):1086-1095. PubMed ID: 33371796
    [No Abstract]   [Full Text] [Related]  

  • 12. Subclassification of Bethesda Atypical and Follicular Neoplasm Categories According to Nuclear and Architectural Atypia Improves Discrimination of Thyroid Malignancy Risk.
    Lim JXY; Nga ME; Chan DKH; Tan WB; Parameswaran R; Ngiam KY
    Thyroid; 2018 Apr; 28(4):511-521. PubMed ID: 29596039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical significance of the American College of Radiology (ACR) Thyroid Imaging Reporting and Data System (TI-RADS) category 5 thyroid nodules: Not as risky as we think?
    Wright K; Brandler TC; Fisher JC; Rothberger GD; Givi B; Prescott J; Suh I; Patel KN
    Surgery; 2023 Jan; 173(1):239-245. PubMed ID: 36511283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in Thyroid Nodule Cytology and Malignancy Risk Between Children and Adults.
    Cherella CE; Angell TE; Richman DM; Frates MC; Benson CB; Moore FD; Barletta JA; Hollowell M; Smith JR; Alexander EK; Cibas ES; Wassner AJ
    Thyroid; 2019 Aug; 29(8):1097-1104. PubMed ID: 31298618
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of the Reclassification of "Noninvasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma" to "Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features" on the Bethesda System for Reporting Thyroid Cytopathology: A Large Academic Institution's Experience.
    Lau RP; Paulsen JD; Brandler TC; Liu CZ; Simsir A; Zhou F
    Am J Clin Pathol; 2017 Dec; 149(1):50-54. PubMed ID: 29272354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 2017 Bethesda System for Reporting Thyroid Cytopathology.
    Cibas ES; Ali SZ
    Thyroid; 2017 Nov; 27(11):1341-1346. PubMed ID: 29091573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) on Malignancy Rates in Thyroid Nodules: How to Counsel Patients on Extent of Surgery.
    Lindeman BM; Nehs MA; Angell TE; Alexander EK; Gawande AA; Moore FD; Doherty GM; Cho NL
    Ann Surg Oncol; 2019 Jan; 26(1):93-97. PubMed ID: 30341576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of the Bethesda Classification for Thyroid Fine-Needle Aspiration: Institutional Experience and Meta-analysis.
    Krauss EA; Mahon M; Fede JM; Zhang L
    Arch Pathol Lab Med; 2016 Oct; 140(10):1121-31. PubMed ID: 27684984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An institutional experience: A retrospective analysis of the effect of transitioning from follicular lesion of undetermined significance to atypia of undetermined significance with subclassified atypia on interobserver concordance, rates of neoplasia, and rates of malignancy.
    Kroll-Wheeler L; Cantley R; Pang JC; Soles BS; Smola B; Jing X; Lew M
    Diagn Cytopathol; 2021 Jan; 49(1):31-38. PubMed ID: 32936526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indeterminate nodules by the Bethesda system for reporting thyroid cytopathology in Israel: Frequency, and risk of malignancy after reclassification of follicular thyroid neoplasm with papillary-like features.
    Rosenblum RC; Shtabsky A; Marmor S; Trejo L; Yaish I; Barnes S; Yehuda M; Stern N; Silman Z; Tordjman KM
    Eur J Surg Oncol; 2019 Jul; 45(7):1182-1187. PubMed ID: 30928335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.